Therapeutic Category: Disease-Modifying Therapies | Neuroprotection
Target: Ferroptosis pathway (lipid peroxidation, iron metabolism)
Indications: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease [1]
Status: Preclinical to Clinical Translation [2]
Ferroptosis Modulation Therapy represents a novel neuroprotective strategy targeting ferroptosis—a regulated form of non-apoptotic cell death driven by iron-dependent lipid peroxidation. This therapeutic approach has emerged as a promising disease-modifying strategy for neurodegenerative diseases, where accumulating evidence demonstrates that neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders involves ferroptotic mechanisms. [3]
The therapy aims to inhibit the ferroptotic cascade through multiple mechanisms: enhancing glutathione peroxidase 4 (GPX4) activity, chelating excess iron, and directly inhibiting lipid peroxidation. By preventing ferroptotic neuronal death, these interventions may slow or halt disease progression in neurodegenerative conditions. [4]
Ferroptosis is morphologically and biochemically distinct from apoptosis, necrosis, and autophagy. It is characterized by: [5]
The ferroptotic cascade begins when the lipid repair capacity—primarily mediated by GPX4—becomes overwhelmed or inactivated. GPX4 is a unique glutathione peroxidase that directly reduces lipid hydroperoxides (LOOH) to corresponding alcohols (LOH), preventing the iron-catalyzed formation of toxic lipid radicals. [6]
GPX4 (Glutathione Peroxidase 4) is the central regulator of ferroptosis. It requires glutathione (GSH) as a cofactor and contains a selenocysteine at its active site. Therapeutic approaches include: [7]
Excess iron is a critical driver of ferroptosis through the Fenton reaction: [8]
Fe2+ + H2O2 → Fe3+ + •OH + OH-
Iron chelation therapies aim to: [9]
Direct inhibitors of lipid peroxidation include: [10]
Since ferroptosis can be regulated by autophagy (particularly ferritinophagy), some therapeutic strategies include autophagy inhibitors to prevent degradation of iron-storage proteins. [11]
Ferrostatin-1 is the prototypical ferroptosis inhibitor, originally developed as a synthetic antioxidant. It functions as a chain-breaking lipid antioxidant that specifically traps lipid peroxyl radicals, preventing the propagation of lipid peroxidation. [12]
| Agent | Mechanism | Clinical Status | Application | [13]
|-------|-----------|-----------------|-------------| [14]
| Deferoxamine (DFO) | Binds Fe3+; limited BBB penetration | Approved for iron overload | Research tool | [15]
| Deferasirox | Oral iron chelator; moderate BBB penetration | Approved for thalassemia | Off-label in NDs | [16]
| Clioquinol | Metal-protein attenuating compound; crosses BBB | Phase 2/3 trials | AD, PD |
| PBT2 | Second-generation copper/zinc modulator | Phase 2 trials | AD |
Multiple studies have demonstrated ferroptosis involvement in AD pathogenesis:
Key studies:
Ferroptosis has been implicated in dopaminergic neuron loss in PD:
Key studies:
| Trial ID | Intervention | Indication | Phase | Status |
|---|---|---|---|---|
| NCT03206684 | Clioquinol | Alzheimer's Disease | Phase 2 | Completed |
| NCT00715403 | PBT2 | Alzheimer's Disease | Phase 2 | Completed |
| NCT01416064 | Deferoxamine | Parkinson's Disease | Phase 2 | Completed |
| NCT00903687 | CoQ10 | Huntington's Disease | Phase 3 | Completed |
| NCT03764280 | Alpha-tocopherol | Alzheimer's Disease | Phase 3 | Recruiting |
Ferroptosis intersects with multiple neurodegenerative disease mechanisms:
Weiland et al. Ferroptosis in Neuronal Death (Antioxidants Redox Signaling, 2019). 2019. ↩︎
Maher et al. Iron Accumulation in Alzheimer's Disease (JAD, 2019). 2019. ↩︎
Zhang et al. GPX4 in Ferroptosis and Neurodegeneration (Cell, 2020). 2020. ↩︎
Hambright et al. Ablation of Ferritinophagy Prevents Ferroptosis (Autophagy, 2017). 2017. ↩︎
Do Van et al. Ferroptosis, a New Mechanism of Neuronal Death in Parkinson's Disease (Movement Disorders, 2016). 2016. ↩︎
Zhang et al. Targeting Ferroptosis in Alzheimer's Disease (Pharmacology, 2021). 2021. ↩︎
Skouta et al. Ferrostatins Inhibit Oxidative Cell Death (JACS, 2014). 2014. ↩︎
Zhang et al. CoQ10 in Neurodegeneration (JND, 2017). 2017. ↩︎
Rembach et al. Clioquinol Reduces Alzheimer's Disease Progression (JAD, 2014). 2014. ↩︎
Devos et al. Neurodegeneration in GPX4 Mouse Models (Nat Neurosci, 2014). 2014. ↩︎
Cui et al. Ferroptosis in ALS (Brain, 2021). 2021. ↩︎
Conrad et al. Selenium in Ferroptosis (Nat Rev Neurosci, 2016). 2016. ↩︎
Kuang et al. Ferroptosis, Autophagy, and Neurodegeneration (Pharmacol Res, 2020). 2020. ↩︎
Wu et al. Iron Metabolism in Neurodegeneration (Prog Neurobiol, 2021). 2021. ↩︎
Jiang et al. Ferroptosis: The Emerging Target for Neurodegenerative Diseases (Aging Dis, 2021). 2021. ↩︎
Chen et al. Lipid Peroxidation in Alzheimer's Disease (JAD, 2020). 2020. ↩︎